| Replication fork stability confers chemoresistance in BRCA-deficient cells A Ray Chaudhuri, E Callen, X Ding, E Gogola, AA Duarte, JE Lee, ... Nature 535 (7612), 382-387, 2016 | 919 | 2016 |
| Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair R Ceccaldi, JC Liu, R Amunugama, I Hajdu, B Primack, MIR Petalcorin, ... Nature 518 (7538), 258-262, 2015 | 917 | 2015 |
| Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer PA Konstantinopoulos, R Ceccaldi, GI Shapiro, AD D'Andrea Cancer discovery 5 (11), 1137-1154, 2015 | 913 | 2015 |
| Association of polymerase e–mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1 BE Howitt, SA Shukla, LM Sholl, LL Ritterhouse, JC Watkins, S Rodig, ... JAMA oncology 1 (9), 1319-1323, 2015 | 668 | 2015 |
| Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade … KC Strickland, BE Howitt, SA Shukla, S Rodig, LL Ritterhouse, JF Liu, ... Oncotarget 7 (12), 13587, 2016 | 629 | 2016 |
| Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets PA Konstantinopoulos, MV Karamouzis, AG Papavassiliou Nature reviews Drug discovery 6 (7), 541-555, 2007 | 620 | 2007 |
| DNA damage and repair biomarkers of immunotherapy response KW Mouw, MS Goldberg, PA Konstantinopoulos, AD D'Andrea Cancer discovery 7 (7), 675-693, 2017 | 600 | 2017 |
| Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer PA Konstantinopoulos, D Spentzos, BY Karlan, T Taniguchi, E Fountzilas, ... Journal of clinical oncology 28 (22), 3555-3561, 2010 | 569 | 2010 |
| PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer L Ding, HJ Kim, Q Wang, M Kearns, T Jiang, CE Ohlson, BB Li, S Xie, ... Cell reports 25 (11), 2972-2980. e5, 2018 | 493 | 2018 |
| Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma PA Konstantinopoulos, S Waggoner, GA Vidal, M Mita, JW Moroney, ... JAMA oncology 5 (8), 1141-1149, 2019 | 485 | 2019 |
| Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids SJ Hill, B Decker, EA Roberts, NS Horowitz, MG Muto, MJ Worley Jr, ... Cancer discovery 8 (11), 1404-1421, 2018 | 406 | 2018 |
| Oestrogen receptor beta (ERβ) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation PA Konstantinopoulos, A Kominea, G Vandoros, GP Sykiotis, ... European journal of cancer 39 (9), 1251-1258, 2003 | 395 | 2003 |
| A single-cell landscape of high-grade serous ovarian cancer B Izar, I Tirosh, EH Stover, I Wakiro, MS Cuoco, I Alter, C Rodman, ... Nature medicine 26 (8), 1271-1279, 2020 | 381 | 2020 |
| Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline PA Konstantinopoulos, B Norquist, C Lacchetti, D Armstrong, RN Grisham, ... Journal of Clinical Oncology 38 (11), 1222-1245, 2020 | 376 | 2020 |
| EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation B Rondinelli, E Gogola, H Yücel, AA Duarte, M van de Ven, ... Nature cell biology 19 (11), 1371-1378, 2017 | 338 | 2017 |
| Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer PA Konstantinopoulos, D Spentzos, E Fountzilas, N Francoeur, ... Cancer research 71 (15), 5081-5089, 2011 | 320 | 2011 |
| Cancer of the cervix, vagina, and vulva PJ Eifel, AH Klopp, JS Berek, PA Konstantinopoulos DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology …, 2018 | 275 | 2018 |
| Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer A Färkkilä, DC Gulhan, J Casado, CA Jacobson, H Nguyen, ... Nature communications 11 (1), 1459, 2020 | 244 | 2020 |
| Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial PA Konstantinopoulos, WT Barry, M Birrer, SN Westin, KA Cadoo, ... The Lancet Oncology 20 (4), 570-580, 2019 | 241 | 2019 |
| PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum … RW Naumann, RL Coleman, RA Burger, EA Sausville, E Kutarska, ... Journal of clinical oncology 31 (35), 4400-4406, 2013 | 226 | 2013 |
